Two Sigma Advisers LP lowered its stake in Enzo Biochem, Inc. (NYSE:ENZ) by 29.0% in the fourth quarter, Holdings Channel reports. The fund owned 101,473 shares of the medical research company’s stock after selling 41,385 shares during the quarter. Two Sigma Advisers LP’s holdings in Enzo Biochem were worth $827,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new position in shares of Enzo Biochem in the third quarter worth about $263,000. Wells Fargo & Company MN lifted its holdings in shares of Enzo Biochem by 54.3% in the third quarter. Wells Fargo & Company MN now owns 302,072 shares of the medical research company’s stock worth $3,163,000 after acquiring an additional 106,342 shares during the last quarter. California Public Employees Retirement System lifted its holdings in shares of Enzo Biochem by 51.1% in the third quarter. California Public Employees Retirement System now owns 86,034 shares of the medical research company’s stock worth $901,000 after acquiring an additional 29,093 shares during the last quarter. Cadence Capital Management LLC bought a new position in shares of Enzo Biochem in the fourth quarter worth about $722,000. Finally, SG Americas Securities LLC bought a new position in shares of Enzo Biochem in the fourth quarter worth about $181,000. 66.15% of the stock is owned by hedge funds and other institutional investors.
In other news, CFO Barry W. Weiner sold 11,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $85,250.00. Following the completion of the transaction, the chief financial officer now owns 1,313,111 shares of the company’s stock, valued at $10,176,610.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Elazar Rabbani sold 14,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $7.75, for a total value of $108,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,867,202 shares of the company’s stock, valued at approximately $14,470,815.50. The disclosure for this sale can be found here. Corporate insiders own 8.90% of the company’s stock.
Enzo Biochem stock opened at $6.15 on Tuesday. Enzo Biochem, Inc. has a 1 year low of $5.35 and a 1 year high of $12.04.
Enzo Biochem (NYSE:ENZ) last released its quarterly earnings data on Monday, March 12th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.03). Enzo Biochem had a negative net margin of 1.38% and a negative return on equity of 2.95%. The firm had revenue of $26.95 million during the quarter, compared to analyst estimates of $27.35 million.
Separately, ValuEngine cut shares of Enzo Biochem from a “hold” rating to a “sell” rating in a report on Thursday, March 1st.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/17/two-sigma-advisers-lp-reduces-stake-in-enzo-biochem-inc-enz.html.
Enzo Biochem Company Profile
Enzo Biochem, Inc, an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics.
Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.